Wed, November 27, 2024
Tue, November 26, 2024
Mon, November 25, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Sat, June 10, 2017
Sat, June 3, 2017
Wed, May 31, 2017
Wed, May 17, 2017
Fri, May 12, 2017
Thu, May 11, 2017
Tue, May 9, 2017
Thu, May 4, 2017
Thu, April 20, 2017
Fri, April 14, 2017
Thu, March 23, 2017
Fri, March 17, 2017
Thu, March 9, 2017
Sat, March 4, 2017
Fri, March 3, 2017
Thu, March 2, 2017
Wed, February 15, 2017
Mon, February 13, 2017
Wed, February 8, 2017
Thu, February 2, 2017
Fri, January 13, 2017
Wed, January 11, 2017
Wed, January 4, 2017
Fri, December 16, 2016
Thu, December 15, 2016
Mon, December 12, 2016
Thu, December 8, 2016
Wed, November 23, 2016
Mon, November 14, 2016
Sun, November 13, 2016
Wed, November 9, 2016
Thu, November 3, 2016
Wed, November 2, 2016
Mon, October 17, 2016
Sat, October 8, 2016
Thu, October 6, 2016
Wed, October 5, 2016
Mon, October 3, 2016
Fri, September 30, 2016
Thu, September 29, 2016
Tue, September 27, 2016
Mon, September 26, 2016
Fri, September 23, 2016
Thu, September 22, 2016
Wed, September 21, 2016
[ Wed, Sep 21st 2016 ] - Market Wire
Last Patient Out
Tue, September 20, 2016
Mon, September 19, 2016
Sun, September 18, 2016
Fri, September 16, 2016
Thu, September 15, 2016
Wed, September 14, 2016
Mon, September 12, 2016
Fri, September 9, 2016
Thu, May 9, 2013
[ Thu, May 09th 2013 ] - Market Wire
Achieves Record Revenues
Wed, May 8, 2013
Tue, May 7, 2013
Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013

Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders


//health-fitness.news-articles.net/content/2013/ .. ctors-at-its-annual-meeting-of-shareholders.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

QUÉBEC CITY, May 8, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: [ AEZS ]) (TSX: AEZ) (the "Company") announces the results of the vote on directors held earlier today at its annual meeting of shareholders. Issuers listed on the Toronto Stock Exchange are required to issue a news release providing this information.

Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the seven directors nominated for election as set forth in the table below:

Name of NomineeVotes For%Votes Withheld%
Marcel Aubut 2,379,194 70.8 979,320 29.2
David A. Dodd* 2,385,312 71.0 973,202 29.0
José P. Dorais 2,692,560 80.2 665,954 19.8
Carolyn Egbert 2,351,610 70.0 1,006,903 30.0
Juergen Ernst 2,339,417 69.7 1,019,097 30.3
Pierre Lapalme 2,375,050 70.7 982,964 29.3
Gérald Limoges 2,380,610 70.9 977,404 29.1
(*)  The results for the proxies received regarding Mr. Dodd were originally received for the Company's former President and Chief Executive Officer and director, Prof. Juergen Engel. As announced by the Company on April 15, 2013, Mr. Dodd succeeded to Prof. Engel as President and Chief Executive Officer, and Mr. Dodd was also concurrently appointed to the Board of Directors. At the same time, the Company announced that Mr. Dodd would be one of the management director nominees for election at the Company's annual meeting of shareholders and that Management proxy holders intended to exercise the discretion granted in the proxies to vote in favour of the election of Mr. Dodd as a director at the shareholders' meeting.

All other matters at the shareholders' meeting, namely the renewal of and amendment to the Company's Stock Option Plan, the reconfirmation and approval of the Shareholder Rights Plan and the confirmation of an amendment to the Company's bylaws, were also approved by shareholders.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit [ www.aezsinc.com ].

SOURCE AETERNA ZENTARIS INC.




Publication Contributing Sources